TY  - JOUR
A1  - Schlecht, Anja
A1  - Wolf, Julian
A1  - Boneva, Stefaniya
A1  - Prinz, Gabriele
A1  - Braunger, Barbara M.
A1  - Wieghofer, Peter
A1  - Agostini, Hansjürgen
A1  - Schlunck, Günther
A1  - Lange, Clemens
T1  - Transcriptional and distributional profiling of microglia in retinal angiomatous proliferation
JF  - International Journal of Molecular Sciences
N2  - Macular neovascularization type 3, formerly known as retinal angiomatous proliferation (RAP), is a hallmark of age-related macular degeneration and is associated with an accumulation of myeloid cells, such as microglia (MG) and infiltrating blood-derived macrophages (MAC). However, the contribution of MG and MAC to the myeloid cell pool at RAP sites and their exact functions remain unknown. In this study, we combined a microglia-specific reporter mouse line with a mouse model for RAP to identify the contribution of MG and MAC to myeloid cell accumulation at RAP and determined the transcriptional profile of MG using RNA sequencing. We found that MG are the most abundant myeloid cell population around RAP, whereas MAC are rarely, if ever, associated with late stages of RAP. RNA sequencing of RAP-associated MG showed that differentially expressed genes mainly contribute to immune-associated processes, including chemotaxis and migration in early RAP and proliferative capacity in late RAP, which was confirmed by immunohistochemistry. Interestingly, MG upregulated only a few angiomodulatory factors, suggesting a rather low angiogenic potential. In summary, we showed that MG are the dominant myeloid cell population at RAP sites. Moreover, MG significantly altered their transcriptional profile during RAP formation, activating immune-associated processes and exhibiting enhanced proliferation, however, without showing substantial upregulation of angiomodulatory factors.
KW  - AMD
KW  - Mactel 2
KW  - macular neovascularization
KW  - MNV type 3
KW  - retinal angiomatous proliferation
KW  - RAP
KW  - microglia
KW  - RNA sequencing
KW  - Cx3cr1
KW  - CreERT2
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284072
SN  - 1422-0067
VL  - 23
IS  - 7
ER  - 
TY  - JOUR
A1  - Grassmann, Felix
A1  - Fritsche, Lars G.
A1  - Keilhauer, Claudia N.
A1  - Heid, Iris M.
A1  - Weber, Bernhard H. F.
T1  - Modelling the Genetic Risk in Age-Related Macular Degeneration
JF  - PLoS One
N2  - Late-stage age-related macular degeneration (AMD) is a common sight-threatening disease of the central retina affecting approximately 1 in 30 Caucasians. Besides age and smoking, genetic variants from several gene loci have reproducibly been associated with this condition and likely explain a large proportion of disease. Here, we developed a genetic risk score (GRS) for AMD based on 13 risk variants from eight gene loci. The model exhibited good discriminative accuracy, area-under-curve (AUC) of the receiver-operating characteristic of 0.820, which was confirmed in a cross-validation approach. Noteworthy, younger AMD patients aged below 75 had a significantly higher mean GRS (1.87, 95% CI: 1.69-2.05) than patients aged 75 and above (1.45, 95% CI: 1.36-1.54). Based on five equally sized GRS intervals, we present a risk classification with a relative AMD risk of 64.0 (95% CI: 14.11-1131.96) for individuals in the highest category (GRS 3.44-5.18, 0.5% of the general population) compared to subjects with the most common genetic background (GRS -0.05-1.70, 40.2% of general population). The highest GRS category identifies AMD patients with a sensitivity of 7.9% and a specificity of 99.9% when compared to the four lower categories. Modeling a general population around 85 years of age, 87.4% of individuals in the highest GRS category would be expected to develop AMD by that age. In contrast, only 2.2% of individuals in the two lowest GRS categories which represent almost 50% of the general population are expected to manifest AMD. Our findings underscore the large proportion of AMD cases explained by genetics particularly for younger AMD patients. The five-category risk classification could be useful for therapeutic stratification or for diagnostic testing purposes once preventive treatment is available.
KW  - AMD
KW  - complement factor-H
KW  - grading system
KW  - United States
KW  - vitamin C
KW  - prevalence
KW  - variants
KW  - susceptibility
KW  - association
KW  - maculopathy
KW  - variant genotypes
KW  - genetic loci
KW  - macular degeneration
KW  - genetics of disease
KW  - eyes
KW  - cased-control studies
KW  - genotyping
KW  - human genetics
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131315
VL  - 7
IS  - 5
ER  -